Celgene Corporation (NASDAQ:CELG) received a $159.00 price objective from investment analysts at Cantor Fitzgerald in a research note issued on Friday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 35.80% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. Vetr cut shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $129.09 price target for the company. in a report on Wednesday, December 14th. Oppenheimer Holdings, Inc. assumed coverage on shares of Celgene Corporation in a report on Tuesday, November 29th. They set an “outperform” rating and a $141.00 price target for the company. Piper Jaffray Companies reiterated a “buy” rating on shares of Celgene Corporation in a report on Tuesday, October 18th. BMO Capital Markets reiterated an “outperform” rating and set a $142.00 price target on shares of Celgene Corporation in a report on Tuesday, December 6th. Finally, Credit Suisse Group reiterated an “outperform” rating and set a $145.00 price target on shares of Celgene Corporation in a report on Tuesday, December 20th. They noted that the move was a valuation call. Four equities research analysts have rated the stock with a hold rating, twenty-six have assigned a buy rating and one has assigned a strong buy rating to the stock. Celgene Corporation currently has an average rating of “Buy” and an average target price of $137.30.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Celgene Corporation (NASDAQ:CELG) traded up 0.62% during mid-day trading on Friday, hitting $117.81. 1,830,928 shares of the stock were exchanged. Celgene Corporation has a 52-week low of $93.05 and a 52-week high of $127.00. The firm has a market cap of $91.33 billion, a price-to-earnings ratio of 44.74 and a beta of 1.74. The company has a 50 day moving average price of $117.82 and a 200 day moving average price of $109.36.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.48 by $0.10. The firm earned $2.98 billion during the quarter, compared to analysts’ expectations of $2.84 billion. Celgene Corporation had a net margin of 19.71% and a return on equity of 70.48%. The business’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 earnings per share. On average, analysts anticipate that Celgene Corporation will post $5.92 EPS for the current year.

WARNING: This news story was first reported by Daily Political and is the propert of of Daily Political. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this news story can be accessed at http://www.dailypolitical.com/2017/01/13/celgene-corporation-celg-given-a-159-00-price-target-by-cantor-fitzgerald-analysts.html.

In other news, major shareholder Corp /De/ Celgene acquired 800,150 shares of the stock in a transaction on Monday, October 24th. The stock was bought at an average price of $14.00 per share, with a total value of $11,202,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael A. Friedman sold 18,600 shares of the stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $116.10, for a total transaction of $2,159,460.00. Following the completion of the sale, the director now directly owns 18,600 shares of the company’s stock, valued at approximately $2,159,460. The disclosure for this sale can be found here. 0.97% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of CELG. Arete Wealth Advisors LLC increased its stake in shares of Celgene Corporation by 0.3% in the third quarter. Arete Wealth Advisors LLC now owns 3,106 shares of the biopharmaceutical company’s stock valued at $325,000 after buying an additional 10 shares during the period. Park National Corp OH increased its stake in shares of Celgene Corporation by 0.4% in the third quarter. Park National Corp OH now owns 3,158 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 12 shares during the period. Proficio Capital Partners LLC increased its stake in shares of Celgene Corporation by 0.9% in the third quarter. Proficio Capital Partners LLC now owns 1,627 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 15 shares during the period. Reynders McVeigh Capital Management LLC increased its stake in shares of Celgene Corporation by 0.4% in the third quarter. Reynders McVeigh Capital Management LLC now owns 6,265 shares of the biopharmaceutical company’s stock valued at $655,000 after buying an additional 24 shares during the period. Finally, Jolley Asset Management LLC increased its stake in shares of Celgene Corporation by 2.1% in the third quarter. Jolley Asset Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 25 shares during the period. 76.32% of the stock is owned by institutional investors.

Celgene Corporation Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.